Title
Predictors of kidney disease progression in diabetes and precision medicine: Something old, something new, and something borrowed
Date Issued
01 September 2021
Access level
open access
Resource Type
editorial
Author(s)
Coca S.G.
Saint Louis University School of Medicine
Publisher(s)
American Society of Nephrology
Wolters Kluwer Health
Start page
2108
End page
2111
Volume
32
Issue
9
Language
English
OCDE Knowledge area
Tecnologías que implican la manipulación de células, tejidos, órganos o todo el organismo
Scopus EID
2-s2.0-85114153984
PubMed ID
Source
Journal of the American Society of Nephrology
ISSN of the container
1046-6673
Sponsor(s)
In the past 3 years, S.G. Coca reports receiving fees for advisory boards or steering committee roles for Akebia, Bayer, Boehringer-Ingelheim, CHF Solutions, ProKidney, Quark, Reprieve Cardiovascular, Renalytix, Takeda, and Vifor; reports owning equity in pulseData and Renalytix; reports having patents and inventions with Renalytix; reports receivingsalary and research support from the NIH (grants U01DK106962, R01DK115562, R01HL85757, R01DK112258, U01OH011326, and R01DK126477), ProKidney, Renalytix, the Renal Research
Sources of information:
Directorio de Producción Científica
Scopus